Free Cash Flow: A measure of financial performance calculated as operating cash flow minus capital expenditures. Calculated as: Cash Flow from Operations + Net Property, Plant & Equipment Exp (a negative number)
Interpace Biosciences, Inc. (IDXG) had Free Cash Flow of $3.38M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$8.76M |
|
$0.91M |
|
$3.32M |
|
$5.44M |
|
$7.61M |
|
$1.15M |
|
$-0.14M |
|
$1.00M |
|
$1.00M |
|
$1.01M |
|
$1.01M |
|
$0.91M |
|
$1.01M |
|
$1.15M |
|
$1.37M |
|
4.42M |
|
27.70M |
|
$0.21 |
|
$0.03 |
|
| Balance Sheet Financials | |
$9.13M |
|
$1.54M |
|
$2.91M |
|
$12.04M |
|
$5.95M |
|
-- |
|
$6.39M |
|
$12.33M |
|
$-0.30M |
|
$-0.30M |
|
$-0.30M |
|
4.43M |
|
| Cash Flow Statement Financials | |
$3.69M |
|
$-0.32M |
|
$-3.41M |
|
$1.46M |
|
$1.42M |
|
$-0.04M |
|
$0.03M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.54 |
|
-- |
|
-- |
|
-- |
|
-3.28 |
|
62.12% |
|
13.08% |
|
13.08% |
|
-- |
|
11.42% |
|
10.40% |
|
|
Free Cash Flow |
$3.38M |
-- |
|
-- |
|
-- |
|
0.73 |
|
-- |
|
1.47 |
|
61.32 |
|
-339.25% |
|
-339.26% |
|
8.40% |
|
-339.26% |
|
$-0.07 |
|
$0.12 |
|
$0.13 |
|